About the Board
A P Offen
Tony Offen has been a Director of Blis Technologies Limited since May 2009 and is the current Chair. Through his Dunedin-based investment company, Edinburgh Securities Limited, Tony is a director and shareholder of a number of successful private companies, including in the commercial and industrial property sectors, FMCG business sectors nationally and internationally, and investment interests requiring venture and start-up capital.
Tony holds professional memberships with the Chartered Accountants Australia and New Zealand and is a Chartered Member of the NZ Institute of Directors. He is an elected member of the National Council for the Neurological Foundation of NZ and is Chairman of its Audit and Risk Committee. Tony is also a member of the Governance Board of Brain Research New Zealand, Centre of Research Excellence (CoRE) and holds a B.Com (Accounting) and B.A. (Philosophy) from University of Otago.
G S Boyd
Graeme Boyd joined ICI New Zealand Limited in 1971 and over 26 years held a variety of positions across the business, including management of the Pharmaceuticals and Consumer Products Division, culminating in the role of NZ General Manager from 1990 to 1997. He was appointed CEO of Comvita Limited in 1998 and developed the company from a small privately-owned company to a publicly-listed company centred on marketing natural health products internationally.
Graeme left Comvita in 2005 and formed a management consulting business specialising in company turnarounds, growth strategies and international marketing. Graeme has been a director of Blis Technologies Limited since July 2014. Graeme holds an MSc from University of Canterbury, is a professional director and a Chartered Member of the Institute of Directors.
V M Aris
Veronica Aris has over 17 years of sales and marketing experience in senior management level positions across many industry sectors, including primary care consumables, pharmaceutical, natural health care supplements, consumer products, DRTV and industrial products for companies such as Sanofi-Synthelabo, Pfizer, Abbott Laboratories, EBOS, Brand Developers and Wesfarmers, within UK, Australia and New Zealand. Her expertise is in the area of pharma product launches, brand management, marketing, sales and regulatory affairs, as well as social media and web strategies. Veronica has been a director of Blis Technologies Limited since July 2014 and was elected Chair of the Remuneration Committee in April 2017. Veronica is passionate about expanding this business into the global market and providing health and wellbeing solutions to a range of communities.
A professional member of the Institute of Directors she holds a number of board positions instilling robust governance practices to enable listed companies, community groups and sporting associations to achieve their long-term goals and vision. She is a Board Member of CASA (working with agencies and communities to help them best manage suicide risk) and Northern Auckland Kindergarten Association, and holds a Chartered Marketer status from the Chartered Institute of Marketers and is a Chartered Member of the Institute of Directors, holds a BSc in Chemistry and French and a DipM in Marketing.
Geoff is currently a Dunedin based Professional Director and Consultant. Geoff is a Fellow of Chartered Accountants Australia and New Zealand, and a Member of the Institute of Directors. Geoff was invited to join the Blis Technologies Ltd Board in May 2018.
Geoff worked for Coopers & Lybrand (now PWC) and KPMG, in Dunedin and Birmingham, UK through the 1980’s before joining Port Otago Ltd in 1988, as Chief Financial Officer. Geoff spent the following 29 years with the Port Otago Group, before retiring in 2017. Geoff worked across the business in a variety of roles, culminating in appointment as CEO in 2004, a position he held until retirement.
Geoff brings significant experience in leading a large successful organization with expertise in logistics, managing international trading relationships, supply chain, human resource, health and safety and risk management. Geoff believes success comes from a focus on quality and delivering outstanding customer service.
Barry Richardson began his career as a scientist at the NZ Dairy Research Institute before joining the NZ Dairy Board in 1985 as a Business Development Manager, undertaking roles in several biotechnology and nutritional Dairy Board joint venture companies.
Barry joined Tatua Co-Op Dairy Company in 1991 as General Manager, Tatua Biologics and was later appointed General Manager, International and Strategic Development commercialising value added dairy ingredients. He was appointed CEO of Westland Milk Products when the Company elected to be an independent exporter of dairy products in late 2001.
From 2006-2016 Barry was CEO of Blis Technologies Limited, through the period when the Company transitioned from a research company into a commercial entity.
Barry has a M.Sc. (Hons) in Biochemistry and a Ph.D. from Massey University. He is a past Fellow of the NZ Institute of Management and a Fellow of the NZ Institute of Food Science and Technology. He was awarded the JC Andrews award for distinction in Food Science and Technology in 2003.
Barry was appointed a director of Blis Technologies Ltd in 2018. His other professional roles include a Director of CertusBio and a Director of CNS Biotechnology.
Dr. A Stewart
Dr. Stewart brings to the board governance and commercial research and development experience within the international biotechnology industry. Dr Stewart has held key executive leadership roles in New Zealand and US corporates and understands the drivers for successful commercialization of research.
Alison is an experienced research and innovation leader with expertise in microbe-based product development, patents, IP protection, new product pipeline and development of strategic partnerships with large international corporations.
Dr. Stewart is currently Chief Executive Officer of the Foundation for Arable Research and in previous roles has lead research centres across NZ, Australia, and the USA. Alison is a Distinguished Emeritus Professor from Lincoln University, NZ and was elected a Companion of the NZ Order of Merit in 2011 for her contributions to biology. Dr. A Stweart joined the Blis Technologies Ltd board on 28 September 2018
Our Senior Management Team
Chief Executive Officer (CEO)
B Com (Marketing), B Ph Ed
Brian was appointed CEO of Blis Technologies in February 2016. He joined Blis following senior management roles with Fonterra and within the Pharmaceutical industry in New Zealand and overseas. Brian’s career has focused on general management, marketing and sales across healthcare, nutraceutical and nutrition industries. Brian has a track record of successfully launching global brands into new markets and leading change within organisations.
Dr John Hale
Chief Technology Officer (CTO)
John Hale did his PhD studying bacteriocins (BLIS) under the supervision of Professor John Tagg at the Department of Microbiology, University of Otago. He carried out post-doctoral research at the University of British Columbia (Vancouver, Canada) and Monash University School of Pharmacy (Melbourne, Australia) investigating the modes of action of antimicrobial peptides. Dr Hale joined Blis Technologies in 2011 and leads the Scientific Services team.
Chief Marketing Officer (CMO)
MBA, BCApSc (Food Science)
Julie joined Blis Technologies in September 2016 as Chief Marketing Officer. Prior to this she spent 18 years working internationally in the FMCG and Pharmaceutical industries in various leadership roles including market research, marketing, operations and change management. Julie returned to NZ in 2014 to take up the CMO role at Dunedin company ADInstruments.
Chief Financial Officer (CFO)
Richard Wingham was appointed to the role of CFO for Blis Technologies in November 2017. Richard is a Chartered Accountant with over 20 years experience, including various senior finance roles across the dairy FMCG, construction and health sectors. His skills cross over manufacturing, project management, information technology and strategic planning.